Gliknik

The company's business model centers on in-house drug discovery and development, followed by strategic partnerships and licensing agreements with major pharmaceutical corporations to manage late-stage clinical trials and commercialization. A landmark achievement was the 2013 exclusive worldwide licensing agreement with Pfizer for the drug candidate GL-2045. This deal included a $25 million upfront payment to Gliknik, with subsequent milestone payments, such as a $15 million payment in 2019 upon the initiation of Phase I trials. This strategy allows Gliknik to generate revenue through upfront payments, milestone achievements, and potential future royalties on net sales, while mitigating the high costs of bringing a drug to market.

Gliknik's product pipeline is built on two primary research platforms. One platform develops immunomodulators, such as cancer vaccines, designed to stimulate the body's own immune system to target and fight tumors. The other key platform is its Stradomer™ technology, which creates recombinant compounds engineered to bind to multiple targets, mimicking the therapeutic effects of Intravenous Immune Globulin (IVIG). GL-2045 (now PF-06755347 under Pfizer) emerged from this platform as a recombinant fusion protein designed to treat autoimmune diseases like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Unlike traditional IVIG derived from thousands of human blood donors, GL-2045 is a recombinant product, which avoids the risk of blood-borne pathogens and can be produced in limitless quantities, potentially addressing chronic supply shortages of IVIG. The company is also advancing other candidates, including GL-0719, a complement modulator for autoimmune diseases, and biropepimut-S for immuno-oncology.